Business context and reporting period
Filing identity: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2016—not a filing identified as Gyre Therapeutics, Inc. Verify the company and filing match the intended request.
Catalyst was a clinical-stage biotechnology company developing engineered protease therapeutics, principally for hemophilia and other bleeding disorders. Its lead candidate, CB 813d (Factor VIIa), had completed an intravenous Phase 1 trial; CB 2679d/ISU 304 (Factor IX) remained in advanced preclinical development. The financial statements are unaudited and compare the second quarter and first six months of 2016 with the corresponding 2015 periods.
Financial performance and position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Contract revenue | $109,000 | $859,000 | $219,000 | $1.531 million |
| Research and development expense | $2.752 million | $1.322 million | $5.046 million | $2.705 million |
| General and administrative expense | $2.272 million | $1.738 million | $4.658 million | $4.060 million |
| Operating loss | $4.915 million | $2.201 million | $9.485 million | $5.234 million |
| Net loss | $4.833 million | $1.724 million | $8.424 million | $4.582 million |
| Basic and diluted loss per share | $0.42 | $4.60 | $0.74 | $12.26 |
Amounts are shown as losses where applicable. The company had no commercial product sales; revenue was contract revenue. Gross margin is not presented, and a meaningful product margin is not available from the filing. The 2015 per-share comparison reflects a substantially lower weighted-average share count following the 2015 merger and reverse split.
- Cash flows, six months: Operating activities used $8.386 million; investing activities used $9.532 million, mainly reflecting purchases of investments; financing activities provided $155,000. Cash and cash equivalents declined $17.763 million to $11.333 million.
- Liquidity at June 30: Cash and cash equivalents were $11.333 million, short-term investments $12.617 million, and restricted cash $30.520 million (including approximately $30.4 million pledged in the notes indenture). Management reported $24.0 million of cash, cash equivalents and short-term investments available and believed resources would fund projected operating needs for at least 12 months.
- Debt and liabilities: Redeemable convertible notes were $30.344 million, versus $33.743 million at year-end 2015. The non-interest-bearing notes are secured by escrowed funds, mature February 2018, and are convertible at the holders’ option. The derivative liability declined to $130,000 from $1.156 million.
- Balance sheet: Total assets were $57.219 million, total liabilities $33.737 million, and stockholders’ equity $23.482 million. Accumulated deficit was $139.461 million.
Changes versus the prior comparable period
- Second-quarter revenue fell 87% and six-month revenue fell 86%, principally because Pfizer terminated its collaboration effective June 2015; Pfizer represented a substantial portion of the earlier-period revenue. ISU Abxis accounted for all 2016 contract revenue.
- Second-quarter R&D expense rose 108% and six-month R&D expense rose 87%, driven by CB 813d manufacturing, higher personnel costs, and preclinical research and laboratory spending.
- Second-quarter net loss increased $3.109 million; six-month net loss increased $3.842 million. Operating expense growth and reduced contract revenue were principal drivers. Six-month interest and other income included a fair-value gain on the notes’ derivative liability.
- Cash and cash equivalents fell from $29.096 million at December 31, 2015, while short-term investments rose from $3.402 million to $12.617 million. The company also redeemed or converted portions of the notes; $6.4 million had been redeemed and $0.3 million converted since the merger, according to the filing.
Outlook, risks and unusual items
- Management expected R&D spending to rise in coming quarters and anticipated significant expenses and operating losses for at least several years. It planned a CB 813d subcutaneous prophylaxis trial in 2017, subject to further development, and reported that ISU Abxis expected to initiate a Phase 1/2 subcutaneous trial of CB 2679d/ISU 304 in 2016.
- On May 20, 2016, Catalyst contracted with CMC ICOS Biologics for CB 813d manufacturing development and production. The initial statement of work totaled $3.8 million; $3.504 million was listed as a contractual obligation at June 30, subject to completion of work stages.
- Management cautioned that its 12-month liquidity assessment depended on assumptions that could prove incorrect. It might need additional equity, debt, collaborations or partnerships; unavailable or inadequate financing could force program delays or cuts. The ATM program had up to $5.8 million remaining for sale as of July 29, 2016.
- The company identified dependence on CB 813d, clinical and regulatory uncertainty, manufacturing and commercialization challenges, competition, and potential dilution or financing constraints as material risks. A weak, transient, non-neutralizing antibody result in one Phase 1 participant was reported; the filing said it might be a false positive and that no neutralizing antibodies were observed.
- After quarter-end, Catalyst completed the sale of certain legacy neural nicotinic receptor assets to Attenua on July 27, 2016. It received the remaining $0.3 million of the approximately $1.0 million upfront consideration and an Attenua warrant; the previously received $0.7 million deposit was recognized in other income at closing.
- The filing reported no material legal proceedings and no off-balance-sheet arrangements. Management said disclosure controls were effective as of June 30, 2016.
Important facts for investors to verify
- Confirm that this Catalyst Biosciences filing, rather than a Gyre Therapeutics filing, is the intended document.
- Reconcile liquidity disclosures: the balance sheet shows $11.333 million cash and $12.617 million short-term investments, while the market-risk section describes $24.0 million as cash and cash equivalents and separately lists $12.6 million of short-term investments. Confirm the intended classification and unrestricted liquidity.
- Review the notes’ escrow and redemption terms, remaining principal, and the effect of future conversions or redemptions on available cash and shares outstanding.
- Assess whether the stated cash runway and planned clinical timelines remain achievable given rising development costs, the $3.504 million CMC obligation, and dependence on external financing.
- Check subsequent clinical developments, the status of the planned CB 813d and CB 2679d/ISU 304 trials, and any safety findings from multiple-dose or subcutaneous studies.
- Verify dilution and share-count changes: the balance sheet reports 11,503,614 shares at June 30, while the filing reports 11,835,864 outstanding as of July 29, 2016.